Average Co-Inventor Count = 5.63
ph-index = 11
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bristol-myers Squibb Compnay (48 from 3,681 patents)
2. Pharmacopeia Inc. (2 from 101 patents)
3. Other (1 from 832,680 patents)
4. Bristol-myers Squibb Pharma Company (234 patents)
49 patents:
1. 12479831 - Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators
2. 12365667 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds
3. 12291522 - Galectin-3 inhibitors
4. 12275719 - Small molecule inhibitors of galectin-3
5. 12269819 - Small molecule inhibitors of Galectin-3
6. 11787779 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds
7. 11597721 - Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses
8. 11286252 - Alkene spirocyclic compounds as farnesoid X receptor modulators
9. 11168079 - Alkene compounds as farnesoid x receptor modulators
10. 11021462 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds
11. 10273237 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
12. 10000480 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
13. 9987266 - Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
14. 9663467 - Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
15. 8685969 - Carboline carboxamide compounds useful as kinase inhibitors